| 1. |
Yusuf S.Two decades of progress in preventing vascular disease.Lancet,2002,360(9326):2-3.
|
| 2. |
Wald NJ,Law MR.A strategy to reduce cardiovascular disease by more than 80%.BMJ,2003,326(7404):1419.
|
| 3. |
Yusuf S,Pais P,Afzal R,et al.Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS):a phase Ⅱ,double-blind,randomized trial.Lancet,2009,373(9672):1341-1351.
|
| 4. |
陈可冀,蒋跃绒.多效药片(polypill)的临床应用与中成药的研发.中国中西医结合杂志,2009,(8):677-679.
|
| 5. |
de Cates AN,Farr MR,Wright N,et al.Fixed-dose combination therapy for the prevention of cardiovascular disease.Cochrane Database Syst Rev,2014,4:CD009868.
|
| 6. |
Huffman MD,de Cates AN,Ebrahim S.Fixed-dose combination therapy (polypill) for the prevention of cardiovascular disease.JAMA,2014,312(19):2030-2031.
|
| 7. |
Zamorano J,Erdine S,Pavia A,et al.Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors:The CRUCIAL trial.Curr Med Res Opin,2011,27(4):821-833.
|
| 8. |
Thom S,Poulter N,Field J,et al.Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD:the UMPIRE randomized clinical trial.JAMA,2013,310(9):918-929.
|
| 9. |
Malekzadeh F,Marshall T,Pourshams A,et al.A pilot double-blind randomized placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors.Int J Clin Pract,2010,64(9):1220-1227.
|
| 10. |
Neutel JM,Bestermann WH,Dyess EM,et al.The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia:A randomized,placebo-controlled,multicenter study.J Clin Hypertens,2009,11(1):22-30.
|
| 11. |
PILL CG.An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.PLoS One,2011,6(5):e19857.
|
| 12. |
Soliman EZ,Mendis S,Dissanayake WP,et al.A Polypill for primary prevention of cardiovascular disease:a feasibility study of the World Health Organization.Trials,2011,12:3.
|
| 13. |
Grimm R,Malik M,Yunis C,et al.Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial.Vasc Health Risk Manag,2010,6:261-271.
|
| 14. |
Wald D,Morris J,Wald N.Randomized polypill crossover trial in people aged 50 and over.PLoS One,2012,7(7):e41297.
|
| 15. |
Yusuf S,Attaran A,Bosch J,et al.Combination pharmacotherapy to prevent cardiovascular disease:present status and challenges.Eur Heart J,2014,35(6):353-364.
|
| 16. |
姚薇,万征.Polypill临床研究进展与应用前景.中国循证心血管医学杂志,2012,4(6):491-493.
|
| 17. |
中国心血管疾病多效复方片研发共识与建议专家组.中国心血管疾病多效复方片研发的共识与建议.中华心血管病杂志,2013,41(2):91-93.
|
| 18. |
单片复方制剂降压治疗中国专家共识专家组.单片复方制剂降压治疗中国专家共识.中华高血压杂志,2012,20(7):624-628.
|
| 19. |
中华医学会心血管病学分会高血压学组.单片复方制剂降压治疗的简易流程.中华高血压杂志,2014,22(11):1021-2013.
|
| 20. |
Feng Y,Xu H,Chen K.Natural polypill Xuezhikang:its clinical benefit and potential multicomponent synergistic mechanisms of action in cardiovascular disease and other chronic conditions.J Altern Complement Med,2012,18(4):318-328.
|
| 21. |
罗国安,梁琼麟,刘清飞,等.复方药物研发创新体系展望.世界科学技术-中医药现代化,2009,11(1):3-10.
|
| 22. |
陶丽,范方田,刘玉萍,等.中药及其组分配伍的整合作用研究实践与进展.中国药理学通报,2013,29(2):153-156.
|
| 23. |
陈可冀.关于复方中成药的临床应用与研究.中国中西医结合杂志,2004,24(4):293.
|
| 24. |
陈莉娜,袁秉祥,王冰.固定剂量复方制剂及其研发现状.中国新药杂志,2013,22(15):1779-1783,1788.
|
